[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"delayed-cerebral-ischemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:delayed-cerebral-ischemia":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,50,78,121,145,171,203],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100642201","phase-4-early-prophylactic-aspirin-for-aneurysmal-subarachnoid-hemorrhage-100642201",false,"NCT07642427","Early Prophylactic Aspirin for Aneurysmal Subarachnoid Hemorrhage","Study on the Efficacy and Safety of Early Prophylactic Use of Aspirin in Improving Prognosis of Patients With Aneurysmal Subarachnoid Hemorrhage: A Multicenter, Prospective, Double-Blind, Randomized Controlled Trial","aSAH-ASA","Inclusion Criteria:\n\n1. Age ≥ 18 years and ≤ 80 years.\n2. Spontaneous subarachnoid hemorrhage (SAH) confirmed by non-contrast head CT.\n3. Diagnosis of ruptured intracranial aneurysm confirmed, and successfully treated by either surgical clipping or endovascular coiling within 48 hours of ictus.\n4. Hunt-Hess grade ≤ 4 or WFNS grade ≤ 4 (assessed within 48 hours of SAH onset).\n5. Fisher grade 2-4 or modified Fisher grade 1-4.\n6. No significant focal neurological deficit after aneurysm intervention, defined as NIHSS scores ≤ 1 in the following items: 5a (left arm motor), 5b (right arm motor), 6a (left leg motor), 6b (right leg motor), and 9 (language).\n7. Pre-morbid modified Rankin Scale (mRS) score ≤ 1 prior to SAH onset.\n\nExclusion Criteria:\n\n1. Hunt-Hess grade 5 or WFNS grade 5 (assessed within 48 hours of SAH onset).\n2. Patients requiring any intracranial stent or non-embolic intrasaccular device during aneurysm embolization, with post-procedural need for antiplatelet therapy.\n3. Angiogram-negative SAH.\n4. Note: Prior history of ruptured intracranial aneurysm or re-rupture of previously treated aneurysm is not excluded.\n5. Moderate-to-severe vasospasm demonstrated on pre-operative or intra-operative CTA\u002FDSA in the emergency setting.\n6. SAH caused by non-saccular aneurysms, including mycotic, blood-blister, fusiform, or dissecting aneurysms, or cases without basal cistern subarachnoid hemorrhage.\n7. Significant pre-existing intracranial pathology at the time of enrollment, including but not limited to: traumatic brain injury, moyamoya disease, high suspicion or documented CNS vasculitis, severe fibromuscular dysplasia, arteriovenous malformation, arteriovenous fistula, significant cervical or intracranial atherosclerotic stenosis (≥70%), or malignant brain tumor.\n8. Medical conditions requiring chronic use of antiplatelet agents (aspirin, clopidogrel, or ticagrelor), such as transient ischemic attack, myocardial infarction, atrial fibrillation, prosthetic heart valve, arteriovenous fistula, unstable angina, or other conditions requiring thromboprophylaxis.\n9. Thrombocytopenia (platelet count \\\u003C20,000\u002FμL, excluding aggregation artifacts), active disseminated intravascular coagulation (DIC) at enrollment, or documented history of coagulopathy or bleeding diathesis.\n10. History of gastrointestinal bleeding or major systemic hemorrhage within 30 days, hemoglobin \\\u003C8 g\u002FdL at admission, INR ≥1.5, or severe hepatic impairment defined as AST, ALT, alkaline phosphatase (AP), or GGT \\>2 times the upper limit of normal.\n11. Creatinine clearance \\\u003C30 mL\u002Fmin.\n12. Severe comorbidities that may confound study outcomes, including but not limited to: multiple sclerosis, dementia, major depression, immunosuppressed state or during intensive immunosuppressive therapy, cancer with expected survival \\\u003C1 year, multi-organ failure, or any other condition potentially causing cognitive impairment.\n13. Contraindications to aspirin therapy, including:\n\n    * Hypersensitivity to aspirin, other salicylates, or any excipients in the formulation;\n    * History of asthma induced by salicylates or NSAIDs;\n    * Active peptic ulcer disease;\n    * Bleeding diathesis;\n    * Hepatic or renal failure;\n    * Uncontrolled severe heart failure;\n    * Concomitant use with methotrexate at doses ≥15 mg\u002Fweek.\n14. Pregnancy or positive HCG test.\n15. Incomplete repair of the responsible aneurysm as judged by the treating physician, with high risk of early re-bleeding.\n16. History of head trauma within 3 months prior to SAH onset.\n17. Recent cerebral disease within 3 months prior to SAH onset, such as tumor, stroke, epilepsy, vasculitis, AVM, or hydrocephalus.\n18. History of psychiatric illness or seizure disorder.\n19. Breastfeeding women.\n20. Expected survival \\\u003C1 year prior to SAH onset.\n21. Participation in another randomized clinical trial that may confound the evaluation of this study.","ALL","18 Years","80 Years",{"count":21,"type":22},388,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","This study is a multicenter, prospective, double-blind, randomized controlled trial designed to evaluate whether early prophylactic use of aspirin improves functional outcomes in patients with aneurysmal subarachnoid hemorrhage (aSAH). Patients with aSAH who have undergone successful aneurysm securing will be randomly assigned to receive either aspirin plus standard care or a placebo plus standard care. The study drug will be started within 48 hours of undergone successful aneurysm securing and continued for not less than 10 days and not more than 14 consecutive days. The main goal is to compare the rate of favorable functional outcomes at 3 months between the two groups. Secondary goals include evaluating the incidence of delayed cerebral ischemia, cerebral infarction, mortality, and safety outcomes such as major bleeding events.",[28,29],"Aneurysmal Subarachnoid Hemorrhage (aSAH)","Delayed Cerebral Ischemia",[31,32,33,34,35,36],"Aneurysmal subarachnoid hemorrhage","Aspirin","Delayed cerebral ischemia","Antiplatelet therapy","Functional outcome","Randomized controlled trial","NOT_YET_RECRUITING","2026-06-07",{"date":40,"type":41},"2026-06-11","ACTUAL",{"date":43,"type":22},"2026-06-01",{"date":45,"type":22},"2029-08",{"name":47,"class":48},"Ganzhou City People's Hospital","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100571704","phase-2-efficacy-of-daily-iv-administration-of-dornase-alfa-up-to-14-days-post-subarachnoid-hemorrhage-on-functional-independence-at-6-months-100571704","NCT06723717","Efficacy of Daily IV Administration of Dornase Alfa up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence at 6 Months","Efficacy of Daily IV Administration of Dornase Alfa up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence at 6 Months: a PROBE Multicenter Open-label Randomized Controlled Trial","RESET","Inclusion Criteria:\n\n* Hospitalization for subarachnoid hemorrhage (SAH) due to aneurysm rupture\n* Onset of SAH symptoms less than 48 hours old\n* Aneurysm exclusion performed within the last 24 hours\n* No complications during exclusion procedure, confirmed on post-procedure CT scan\n* Fisher score \\> 1 on initial brain CT scan prior to exclusion (first scan performed during emergency management)\n\nExclusion Criteria:\n\n* Unidentified date of aneurysm rupture \u002F rebleeding\n* Severe infections\n* Patient with impaired renal function (GFR \\\u003C 60ml\u002Fmin\u002F1.73m2 or serum creatinine \\>1.5 mg\u002FdL)\n* Immediate complications of neurosurgical intervention or embolization\n* Known hypersensitivity to dornase alfa, Chinese hamster ovary cell products or product excipients.\n* Previous disability (mRS\\>1 prior to SAH)\n* Pregnant or breast-feeding women (negative urine pregnancy test for women aged 49 or under)\n* Participation in another interventional drug or medical device clinical trial within the 30 days prior to inclusion.",{"count":59,"type":22},304,[61],"PHASE2","Subarachnoid hemorrhage due to aneurysm rupture (SAH) results in high mortality, while survivors frequently suffer reduced quality of life and even loss of autonomy, particularly in the active population. A significant proportion of this morbidity and mortality is linked to the occurrence of delayed cerebral ischemia (DCI), defined as a new focal neurological deficit or reduced level of consciousness unrelated to the treatment of the aneurysm or a concomitant condition.\n\nDCI mainly occurs between days 4 and 14 after SAH, with an estimated incidence of 30%, and is significantly associated with an unfavorable functional prognosis at 3 months. Currently, the only treatment for post-SAH DCI is to prevent or reverse the onset of vasospasm, with limited efficacy, for example through nimodipine administration or hemodynamic optimization. However, according to existing data, vasospasm is not the only cause of DCI, as it may occur elsewhere than in the arterial territory affected by vasospasm, or even in the absence of any vasospasm at all. Recent reviews of the literature highlight the role of microvascular thrombo-inflammation in the pathophysiology of DCI.\n\nThis phenomenon begins as soon as SAH occurs, with the appearance of multiple microvascular obstructions responsible for ischemia of downstream territories and loss of distal autoregulatory capacity. Among the effectors of thrombo-inflammation, the NETose phenomenon (production of NETs - Neutrophil Extracellular Traps or extracellular DNA network) has recently been associated with the onset of DCI. Indeed, the concentration of NETs increases in the cerebrospinal fluid (CSF) and blood of SAH patients, and correlates with the severity of the hemorrhage. Furthermore, intravenous or intraperitoneal administration of DNAse in an animal model of SAH has been shown to reduce NET concentration and improve functional prognosis by acting directly on cerebral perfusion through the reduction of micro-thrombosis.\n\nIn humans, recombinant DNAse (dornase alfa, Pulmozyme®) has marketing authorization for inhaled administration in cystic fibrosis. The toxicology report accompanying the marketing authorization demonstrates the absence of serious side effects following administration of high IV doses of Pulmozyme® in monkeys and rats. Other studies evaluating IV administration of bovine DNAse at high doses report no complications.\n\nIn 1999, a study was published evaluating intravenous (IV) Pulmozyme® in lupus patients, reporting no serious adverse events (SAEs) among the 14 patients receiving the treatment. We are currently conducting a clinical trial of the same molecule in IV administration in patients treated with mechanical thrombectomy and IV thrombolysis for ischemic stroke (NCT04785066).\n\nThis study is the first randomized clinical trial to target NETs as effectors of the thrombo-inflammation responsible for post-HSA DCI.",[64,65,29],"Ruptured Aneurysm of Intracranial Artery","SAH (Subarachnoid Hemorrhage)","RECRUITING","2026-05-07",{"date":69,"type":41},"2026-05-08",{"date":71,"type":41},"2025-09-26",{"date":73,"type":22},"2028-09",{"name":75,"class":76},"Fondation Ophtalmologique Adolphe de Rothschild","NETWORK",6,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":87,"briefSummary":89,"conditions":90,"keywords":94,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":49},"100638580","noninvasive-ca-monitoring-validation-and-autonomic-modulation-in-aneurysmal-subarachnoid-hemorrhage-100638580","NCT07577739","Noninvasive CA Monitoring Validation and Autonomic Modulation in Aneurysmal Subarachnoid Hemorrhage","Non-Invasive Cerebral Autoregulation Monitoring Validation and Autonomic Modulation in Aneurysmal Subarachnoid Hemorrhage: A Two-Component Prospective Study of EVD Clamping Validation, CA Natural History, and the Effects of Cervical Sympathetic Block and Transcutaneous Auricular Vagal Nerve Stimulation on Cerebral Autoregulation Parameters","Inclusion Criteria (Component 1 - All Enrolled Participants):\n\n* Age 18 years or older\n* Primary diagnosis of aneurysmal subarachnoid hemorrhage (aSAH), confirmed by imaging\n* Admitted to the NSICU at Clements University Hospital, UT Southwestern Medical Center\n* Informed consent obtained from subject or legally authorized representative (as defined under Texas Health and Safety Code Section 166.039)\n* Brain4Care extensometry sensor placeable at an appropriate cranial site not occluded by surgical dressings or EVD hardware\n* Open EVD with active continuous ICP monitoring (required for EVD clamping sub-protocol only; not required for Aims 2 or 3)\n\nExclusion Criteria (Component 1):\n\n* Age younger than 18 years\n* Prisoner status\n* Primary NSICU admission diagnosis other than aSAH\n* Active declination by subject or legally authorized representative\n* Brain4Care sensor not placeable at any accessible cranial site\n* Active clinical deterioration making research monitoring impractical at time of approach\n* Physician-of-record declining research enrollment for clinical reasons\n* Inability to provide informed consent in English\n* Known pregnancy at time of enrollment\n\nAdditional Inclusion Criteria for Component 2 (Aim 3 - CSB and taVNS):\n\n* At least one successful EVD clamping session completed\n* PI documentation of Component 2 operational readiness, co-signed by qualified co-investigator or Department Director\n* INR 1.5 or less and platelet count 50,000\u002FuL or greater within 24 hours prior to each CSB procedure\n* No active infection or cellulitis at right anterolateral neck\n* No known allergy to ropivacaine or amide local anesthetics\n* No contralateral phrenic nerve palsy or severe pre-existing respiratory compromise\n* No cardiac pacemaker or implanted cardiac device contraindicating taVNS\n* No allergy to electrode adhesive materials\n* Continuous cardiac telemetry active and interpretable\n* Resting HR 60 bpm or greater on two readings within 24 hours prior to session\n* No current use of Class I or III antiarrhythmic medications\n* No clinically significant AV conduction abnormality\n\nAdditional Exclusion Criteria for Component 2:\n\n* Prior ipsilateral right-sided cervical surgery, radiation, or known anatomical distortion precluding safe C6 approach\n* Hemodynamic instability with active vasopressor escalation at time of planned CSB\n* Active uncontrolled tachyarrhythmia or bradyarrhythmia at time of taVNS session\n* Physician-of-record declining autonomic modulation procedures for any clinical reason\n* Known or suspected pregnancy",{"count":86,"type":22},300,[88],"NA","This is a two-component prospective study of adult aneurysmal subarachnoid hemorrhage (aSAH) patients admitted to the Neurosciences Intensive Care Unit (NSICU) at UT Southwestern Medical Center. Component 1 (active upon IRB approval) validates Brain4Care (B4C) extensometry-derived noninvasive cerebral autoregulation (CA) indices against invasive ICP-derived equivalents in aSAH patients with open external ventricular drains (EVDs), and characterizes the prospective natural history of multi-modal CA parameter evolution through the delayed cerebral ischemia (DCI) window (admission through Day 14). Component 2 (activated upon PI readiness declaration) assesses the within-subject effect of cervical sympathetic block (CSB) and transcutaneous auricular vagal nerve stimulation (taVNS) on CA parameters in enrolled aSAH patients.",[91,29,92,93],"Subarachnoid Hemorrhage, Aneurysmal","Cerebral Vasospasm","Autonomic Nervous System Diseases",[95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111],"aneurysmal subarachnoid hemorrhage","delayed cerebral ischemia","cerebral autoregulation","CPPopt","MAPopt","pressure reactivity index","Brain4Care","cervical sympathetic block","stellate ganglion block","transcutaneous auricular vagal nerve stimulation","taVNS","autonomic modulation","EVD clamping","external ventricular drain","near-infrared spectroscopy","noninvasive ICP monitoring","neurocritical care","2026-05-04",{"date":114,"type":41},"2026-05-11",{"date":116,"type":22},"2026-07",{"date":118,"type":22},"2030-06",{"name":120,"class":48},"University of Texas Southwestern Medical Center",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":23,"phases":132,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":141,"leadSponsor":143,"locationsCount":49},"100582451","phase-1-tocilizumab-aazg-for-hemorrhage-reduction-of-ischemic-vascular-events-100582451","NCT06863480","Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events","THRIVE: Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events","THRIVE","Inclusion Criteria:\n\n* Adult patients (aged ≥18 years) with Hunt Hess Grade 1-3, Fisher score 3 or 3 and 4, aneurysmal subarachnoid hemorrhage within 24 hours of symptom onset (ruptured aneurysm confirmed by CTA, MRA or DSA)\n* Must have external ventricular drain or lumbar drain, or plan to place an external ventricular drain or lumbar drain.\n* Female subjects of child-bearing potential must have negative pregnancy test\n* Signed informed consent from subject or legally authorized representative\n* Able and willing to comply with followup visits\n* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, as defined below:\n\nWomen must remain abstinent or use non-hormonal contraceptive methods with a failure rate of 1% per year during the treatment period and for 2 months after the final dose of TYENNE. Women must refrain from donating or storing eggs during the same time period. A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (12 continuous months of amenorrhea with no identified cause other than menopause), and is not permanently infertile due to surgery (i.e., removal of ovaries, fallopian tubes, and\u002For uterus) or another cause as determined by the investigator (e.g., Müllerian agenesis). The definition of childbearing potential may be adapted for alignment with local guidelines or regulations.\n\nThe reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. If required per local guidelines or regulations, locally recognized acceptable methods of contraception and information about the reliability of abstinence will be described in the local Informed Consent Form.\n\nThe following are examples of adequate non-hormonal contraceptive methods: bilateral tubal ligation; male sterilization; copper intrauterine devices; male or female condom with or without spermicide; and cap, diaphragm, or sponge with spermicide.\n\n• For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined below: With a female partner of childbearing potential or pregnant female partner, men must remain abstinent or use a condom during the treatment period and for 2 months after the dose of TYENNE to avoid exposing the embryo. Men must refrain from donating sperm during this same period.\n\nThe reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of preventing drug exposure. If required per local guidelines or regulations, information about the reliability of abstinence will be described in the local Informed Consent Form.\n\nExclusion Criteria:\n\n* Evidence for vasospasm or DCI prior to study enrollment\n* Hemodynamically unstable pre-enrollment\n* Severe or unstable concomitant condition or disease (e.g., known significant neurological deficit, cancer, hematologic or coronary disease), or chronic condition (e.g., liver disease, kidney disease, or psychiatric disorder), that may increase the risk associated with study participation, or may interfere with the interpretation of study results\n* Subjects who have received an investigational product or participated in another interventional clinical study within 30 days prior to enrollment.\n* Known hypersensitivity or severe allergic reaction to tocilizumab and\u002For other biologics agents (i.e. shock, anaphylactic reactions)\n* Serious infection defined as pneumonia, sepsis\u002Fseptic shock, and neutropenic fever prior to enrollment\n* Any previous treatment with IL-6 inhibitory therapy (e.g. satralizumab), alemtuzumab, etc.\n* Total body irradiation or bone marrow transplantation within 6 months prior to baseline.\n* Any previous treatment with anti-CD20, anti-CD19, eculizumab, belimumab, interferon, natalizumab, glatiramer acetate, fingolimod, teriflunomide or dimethyl fumarate within 6 months prior to baseline.\n* Any previous treatment with anti-CD4, cladribine or mitoxantrone within 2 years prior to baseline\n* Pregnant or breastfeeding, or intending to become pregnant during the study or within 2 months after TYENNE administration\n* Women of childbearing potential must have a negative serum pregnancy test result prior to initiation of study drug.\n* Any surgical procedure (except for minor surgeries) within 4 weeks prior to baseline.\n* Evidence of serious uncontrolled concomitant diseases that may preclude patient participation, such as: other nervous system disease, cardiovascular disease, hematologic\u002Fhematopoiesis disease, respiratory disease, muscular disease, endocrine disease, renal\u002Furologic disease, digestive system disease, congenital or acquired severe immunodeficiency.\n* Known active infection (excluding fungal infections of nail beds or caries dentium) within 4 weeks prior to baseline.\n* History of diverticulitis that, in the principal investigator's opinion, may lead to increased risk of complications such as lower gastrointestinal perforation.\n* Evidence of active or untreated latent tuberculosis (TB; excluding patients receiving chemoprophylaxis for latent TB infection).\n* Evidence of active interstitial lung disease\n* Receipt of any live or live attenuated vaccine within 6 weeks prior to baseline and throughout the duration of the study.\n* History of malignancy within the last 5 years, including solid tumors, hematologic malignancies and in situ carcinoma (except basal cell and squamous cell carcinomas of the skin, or in situ carcinoma of the cervix uteri that have been completely excised and cured).\n* Laboratory exclusion criteria (at screening):\n* White blood cells (WBC) \\\u003C3.0 x103\u002FμL\n* Absolute neutrophil count (ANC) \\\u003C2.0 x103\u002FμL\n* Absolute lymphocyte count \\\u003C0.5 x103\u002FμL\n* Platelet count \\\u003C100 x 103\u002FμL\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\>1.5 times the upper limit of normal (ULN).\n* Patient with known medical history at screening listed for the following must be excluded from this trial:\n* Evidence of chronic active hepatitis B (HBV)\n* Evidence of chronic active hepatitis C (HCV)\n* Positive for hepatitis C virus (HCV) antigen\n* Positive for hepatitis B surface antigen (HBsAg)\n* Known HIV infection.\n* Illicit drug or alcohol abuse within 12 months prior to screening, in the investigator's judgment\n* Poor peripheral venous access\n* Serious infection requiring oral or IV antibiotics prior to screening\n* Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study\n* History or presence of an abnormal ECG that is clinically significant in the investigator's opinion, including complete left bundle branch block, second- or third-degree atrioventricular heart block, or evidence of prior myocardial infarction","89 Years",{"count":131,"type":22},30,[133],"PHASE1","In this study, tocilizumab-aazg (TYENNE) will be administered to see whether tocilizumab-aazg is safe in patients with a burst brain aneurysm and if it may prevent strokes in patients with a burst brain aneurysm.",[136,29],"Aneurysmal Subarachnoid Hemorrhage","2026-03-02",{"date":139,"type":41},"2026-03-04",{"date":137,"type":41},{"date":142,"type":22},"2028-10-30",{"name":144,"class":48},"University of Florida",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":23,"phases":155,"briefSummary":156,"conditions":157,"keywords":158,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":49},"100518591","remote-ischemic-conditioning-in-aneurysmal-sah-100518591","NCT06032533","Remote Ischemic Conditioning in Aneurysmal SAH","The Effect of Remote Ischemic Conditioning on Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage: A Prospective, Randomized, Patient-assessor Blinded, Sham-controlled Pilot Study Investigating Effect on Clinical Outcome.","RESCUE-SAH","Inclusion Criteria:\n\n* Aneurysmal subarachnoid hemorrhage confirmed by computed tomography (CT) with aneurysm origin confirmed by computed tomography angiography (CTA) or digital subtraction angiography (DSA)\n* Aneurysmal subarachnoid hemorrhage symptom-onset ≤ 3 days\n* Aneurysm protected by clipping or coiling\n* Independent in daily living before symptom onset (mRS ≤ 2)\n\nExclusion Criteria:\n\n* Subarachnoid hemorrhage caused by a lesion other than cerebral aneurysm\n* Symptomatic vasospasm at the time of enrollment\n* Previous cerebral lesion e.g. symptomatic cerebral infarction (\\>2cm), multiple sclerosis, symptomatic intracerebral hemorrhage, tumour, prior neurosurgery (excluding prior clipping or coiling of cold aneurysms without complications).\n* History of severe peripheral vascular disease or signs of severe peripheral vascular disease on physical examination\n* History of deep vein thrombosis or signs of deep vein thrombosis on physical examination\n* Kidney involvement or prior kidney disease with an estimated glomerular filtration rate (eGFR) below safe levels for contrast infusion in relation to CT-perfusion.\n* Pregnancy (Women of child-bearing age will have serum-Humane Choriogonadotropine taken prior to final inclusion. If pregnancy cannot be ruled out,the patient can't be included. Women with a safe birth control method will be encouraged to use this method during the entire period of active treatment.)\n* Concomitant other acute life-threatening medical or surgical condition",{"count":154,"type":22},100,[88],"The goal of this clinical trial is to examine the effect of limb occlusion therapy (remote ischemic conditioning, RIC) in subjects with aneurysmal subarachnoid hemorrhage.\n\nThe main question it aims to answer is whether RIC can improve long-term recovery in participants with aneurysmal subarachnoid hemorrhage.\n\nResearchers will compare levels of functional independence in participants in the RIC-group to participants in the sham-group.",[91,29],[159,160,161,29],"Remote Ischemic Conditioning","Subarachnoid Hemorrhage","Aneurysm","2025-09-30",{"date":164,"type":41},"2025-10-03",{"date":166,"type":41},"2023-09-09",{"date":168,"type":22},"2027-11-30",{"name":170,"class":48},"Aarhus University Hospital",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":178,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":179,"targetDuration":4,"studyType":181,"phases":4,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":49},"100585750","mechanisms-of-brain-heart-injury-of-post-intracranial-hemorrhage-100585750","NCT06906432","Mechanisms of Brain-Heart Injury of Post-Intracranial Hemorrhage","Multimodal Omics and Imaging Study on the Mechanisms of Brain-heart Injury in Patients With Intracranial Hemorrhage","Inclusion Criteria:\n\n1. Patients aged 18 years or older at the time of enrollment.\n2. Acute intracranial hemorrhage confirmed by neuroimaging (CT, MRI，CTA, MRA, or DSA) within 48 hours of symptom onset.\n3. Ability to provide informed consent or have a legally authorized representative willing to consent on their behalf.\n\nExclusion Criteria:\n\n1. Patients who refuse to participate in the study or cannot provide informed consent.\n2. Patients with a history of significant cardiovascular disease, including myocardial infarction, heart failure, or arrhythmias, unless stable and well-controlled.\n3. Patients who have undergone cardiac bypass surgery, stent placement, or other cardiovascular interventions within the past 6 months.\n4. Patients with active brain tumors, ischemic stroke within 3 months or a history of previous brain injury that could confound the study findings.\n5. Patients with active malignant disease, severe inflammatory or infectious disease, or those who have undergone surgery for any reason within the past 3 months.\n6. Patients with any condition that, in the opinion of the investigator, would make it unsafe or impractical to participate in the study.",true,{"count":180,"type":22},1000,"OBSERVATIONAL","Intracranial hemorrhage is a condition characterized by high mortality rates and suboptimal functional outcomes. It precipitates both direct brain injury and subsequent secondary injuries, including delayed cerebral ischemia, brain edema, and hydrocephalus. Complications such as cardiac injury may also arise, categorizing them within the cerebrocardiac syndrome (CCS). The clinical spectrum of CCS encompasses acute myocardial injury, acute coronary syndrome, left ventricular systolic and diastolic dysfunction, cardiac arrhythmias, and sudden cardiac death, all of which are associated with increased mortality and deterioration in patient status. The precise pathophysiological mechanisms underlying both cerebral and cardiac injuries remain enigmatic, and the implications for diagnosis and therapeutic strategies are yet to be fully explored.\n\nIn this study, we propose to enroll patients with intracranial hemorrhage who will undergo conventional treatment and comprehensive multidisciplinary evaluations. Our observational research is grounded in a multimodal omics and imaging approach, aimed at investigating both local and systemic injuries subsequent to intracranial hemorrhage. This comprehensive strategy is intended to facilitate precise diagnosis, risk stratification, and clinical decision-making, while also shedding light on the pathophysiological mechanisms involved.\n\nThe primary objectives of this research are to address the following key questions:\n\n* \\[Question 1\\] What are the pathophysiological mechanisms underlying cardiac injury in patients with intracranial hemorrhage?\n* \\[Question 2\\] What are the pathophysiological mechanisms responsible for early and delayed brain injuries following intracranial hemorrhage?\\"",[91,184,185,186,187,188,189,190,29,191,192,193],"Cerebrocardiac Syndrome","Mass Spectrometry","Heart Failure","Atrial Fibrillation","Ischemic Heart Disease","Heart Infarction","Arrhythmias, Cardiac","Hydrocephalus","Vasospasm, Cerebral","Intracerebral Hemorrhage","2025-03-29",{"date":196,"type":41},"2025-04-02",{"date":198,"type":41},"2024-08-01",{"date":200,"type":22},"2036-12-01",{"name":202,"class":48},"Beijing Tiantan Hospital",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":23,"phases":211,"briefSummary":212,"conditions":213,"keywords":214,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":49},"100401433","phase-2-improving-outcome-in-subarachnoid-hemorrhage-with-nadroparine-100401433","NCT04507178","Improving Outcome in Subarachnoid Hemorrhage wIth Nadroparine","ISCHEMIA","Inclusion Criteria:\n\n* SAH confirmed by CT or lumbar puncture with the causative aneurysm confirmed by CT-A and\u002For digital subtraction angiography\n* Coiling of the causative aneurysm within 72 hours of initial SAH\n* Informed consent within 24 hours after coiling\n\nExclusion Criteria:\n\nStent-assisted coiling\n\n* Use of anticoagulant medication post-coiling for other reasons\n* Contra-indications for LMWH:\n\n  * Previous history of history of heparin-induced thrombocytopenia\n  * (Suspicion of) active arterial or venous bleeding\n  * Previous history of hemorrhagic diathesis due to coagulation disorders (with the ex-ception of disseminated intravascular coagulation)\n  * Severe hypertension: uncontrolled hypertension with a mean arterial pressure \\>135mmHg\n  * Previous history of hypertensive or diabetic retinopathy\n  * Previous history of active infectious endocarditis\n  * Severe renal impairment (creatinine clearance \\\u003C30 mL \u002F min)\n* No proficiency of Dutch or English language",{"count":154,"type":22},[61],"Delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage (aSAH) was long thought to be caused by subarachnoid blood-induced vasospasm. Experimental and clinical evidence suggest activation of several pathophysiological pathways, affecting the cerebral microcirculation. Recently, lower in-hospital mortality and less non-home discharge was reported in patients treated with therapeutic low-molecular weight heparin (LMWH), compared to patients with standard, prophylactic LMWH, pointing towards a potential benefit of higher doses of LMWH in the acute course after aSAH. Treatment with therapeutic LMWH might improve clinical outcome in endovascularly treated aSAH patients.\n\nThe primary objective is to evaluate whether aSAH patients treated with therapeutic LMWH have a lower 30-day mortality rate compared to patients treated with prophylactic LMWH. Secondary objectives are to evaluate whether there are significant differences between patients treated with therapeutic and prophylactic LMWH in development of DCI, (hemorrhagic) complications during admission, hydrocephalus, non-home discharge location, quality of life, clinical outcome and cognitive functioning at three and six months, total health care costs.\n\nA single center, prospective, phase II randomized clinical trial in aneurysmal SAH patients ≥18 years old, in whom the causative aneurysm is treated with endovascular coiling less than 72 hours after initial SAH.\n\nPatients are randomized into 2 groups: (1) Therapeutic dose LMWH group: the standard prophylactic dose, administered upon hospital admission, will be replaced by nadroparin s.c. twice daily 5700 IE anti-Xa, starting within 24 hours after coiling and continued until 21 days after ictus of initial SAH. After 21 days, patients will continue with standard care prophylactic dose until discharge or when mobilized for more than 6 hours per day; (2) Control group: standard of care treatment with prophylactic dose of LMWH; nadroparin, s.c. once daily 2850 AxaIU until discharge or when mobilized for at least 6 hours a day.\n\nPrimary outcome: 30-days' mortality. Secondary outcome: DCI, venous thrombo-embolic complications, occurrence of major and non-major bleeding, hemorrhagic complications after external ventricular\u002Flumbar drain (EVD\u002FELD) placement and lumbar puncture (LP), other SAH-related complications, shunt-dependent hydrocephalus, discharge location, quality of life, total health care costs, cognitive functioning, clinical outcome.",[136,29],[215,216,217,96],"nadroparin","subarachnoid hemorrhage","brain ischemia","2025-01-27",{"date":220,"type":41},"2025-01-29",{"date":222,"type":41},"2022-02-02",{"date":224,"type":22},"2027-04-01",{"name":226,"class":48},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)"]